Zileuton
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Zileuton?
Summarize this article for a 10 year old
Zileuton (trade name Zyflo) is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, used for the maintenance treatment of asthma. Zileuton was introduced in 1996 by Abbott Laboratories and is now marketed in two formulations by Cornerstone Therapeutics Inc. under the brand names Zyflo and Zyflo CR. The original immediate-release formulation, Zyflo, is taken four times per day. The extended-release formulation, Zyflo CR, is taken twice daily.
Clinical data | |
---|---|
Pronunciation | /zaɪˈluːtən/ zy-LOO-tən |
Trade names | Zyflo |
AHFS/Drugs.com | Monograph |
MedlinePlus | a697013 |
License data | |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Not yet established |
Protein binding | 93% |
Metabolism | Hepatic (CYP1A2, CYP2C9 and CYP3A4-mediated) |
Elimination half-life | 2.5 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL |
|
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.121.111 |
Chemical and physical data | |
Formula | C11H12N2O2S |
Molar mass | 236.29 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(verify) |
Although the 600 mg immediate release tablet (Zyflo) and extended release formulation of zileuton are still available (Zyflo CR), the 300 mg immediate release tablet was withdrawn from the U.S. market on February 12, 2008.[1][2]